Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead [PDF]
Journal of Hematology & OncologyThe AML treatment landscape has significantly changed in recent years with the approval of targeted therapies in the front-line and relapsed/refractory settings, including inhibitors of FLT3 and IDH1/2 mutations.
Kalyan V. G. Nadiminti +2 more
doaj +3 more sources
Therapeutic Implications of Menin Inhibitors in the Treatment of Acute Leukemia: A Critical Review [PDF]
DiseasesMenin inhibitors are a class of targeted agents that exemplify how a deeper understanding of leukemia pathogenesis can unify seemingly distinct genetic acute leukemia subgroups under a common therapeutic strategy.
Martina Canichella +3 more
doaj +3 more sources
The promise of menin inhibitors: from approval to triplet regimens. [PDF]
Hematology Am Soc Hematol Educ ProgramAbstract Pharmacologic targeting of the menin-KMT2A protein–protein interaction has emerged as a therapeutic breakthrough for acute leukemias harboring KMT2A rearrangements or NPM1 mutations. The first-in-class menin inhibitor (revumenib) achieved accelerated regulatory approval in November 2024 for monotherapy of relapsed/refractory ...
Thakur RK, Wang ES.
europepmc +3 more sources
Menin inhibitors in the treatment of acute myeloid leukemia
BloodAbstract Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the (oligo)clonal expansion of myeloid progenitor cells. Despite advances in treatment, AML remains challenging to cure, particularly in patients with specific genetic abnormalities.
Gerwin Huls +2 more
openaire +3 more sources
Design of Inhibitors That Target the Menin–Mixed-Lineage Leukemia Interaction
Computation, 2023 The prognosis of mixed-lineage leukemia (MLL) has remained a significant health concern, especially for infants. The minimal treatments available for this aggressive type of leukemia has been an ongoing problem.
Moses N. Arthur +8 more
doaj +2 more sources
Research progress in Menin-MLL interaction and its inhibitors in MLL-rearranged leukemia
Shanghai Jiaotong Daxue xuebao. Yixue banAcute leukemias caused by mixed lineage leukemia (MLL) gene rearrangements (MLL-r) are characterized by high invasiveness and a poor prognosis, with few specific treatment options available.
FANG Xinyue +5 more
doaj +2 more sources
Nature CommunicationsTargeting the dependency of MLL-rearranged (MLLr) leukemias on menin with small molecule inhibitors has opened new therapeutic strategies for these poor-prognosis diseases.
Xiangguo Shi +23 more
doaj +2 more sources
Menin Inhibition in Acute Myeloid Leukemia: Pathobiology, Progress and Promise
BiomedicinesAcute myeloid leukemia (AML) is a highly aggressive malignancy defined by significant biological diversity and variable patient outcomes. A key subset of AML is driven by abnormalities that lead to the overexpression of the oncogenic transcription ...
Utsav Joshi, Rory M. Shallis
doaj +2 more sources
Targeting the menin-MLL-LEDGF Interaction with Small Molecule Inhibitors. [PDF]
, 2016 Mixed Lineage Leukemia 1 (MLL) is a large multi-domain protein (430 kDa) encoded by the MLL gene that catalyzes the methylation of histone H3 lysine 4 (H3K4).
Pollock, Jonathan
core +7 more sources
Therapeutic Advances in Adult B-cell Acute Lymphoblastic Leukemia with KMT2A Rearrangements [PDF]
Annals of HematologyB-cell acute lymphoblastic leukemia (ALL) with KMT2A rearrangements (KMT2Ar B-ALL) represents a distinct, high-risk subtype in adults, characterized by aggressive disease biology, high relapse rates, and inferior long-term survival.
Shen-Hao Liu +5 more
doaj +2 more sources